Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 19/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036408 | 0.96 | TNF (0.47) | TNFGAA | |
| SCHEMBL7036369 | 0.85 | MTNR1A (0.38) | TNF | |
| SCHEMBL7038766 | 0.85 | KDM4E (0.46) | — | |
| SCHEMBL6778694 | 0.78 | PDE4D (0.35) | — | |
| SCHEMBL4251804 | 0.72 | TNF (0.56) | TNF | |
| SCHEMBL9412552 | 0.71 | TNF (0.53) | TNF | |
| SCHEMBL11210331 | 0.70 | TNF (0.58) | TNFGAA | |
| SCHEMBL12519127 | 0.70 | TNF (0.55) | TNFGAA | |
| SCHEMBL10974103 | 0.68 | TNF (0.61) | TNFGAA | |
| SCHEMBL9305415 | 0.68 | ALDH1A1 (0.44) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114445-A1 | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| WO-2003011297-A1 | N3-SUBSTITUTED 6-ANILINOPYRIMIDINES AND METHODS TO TREAT GRAM-POSITIVE BACTERIAL AND MYCOPLASMAL INFECTIONS | UNIVERSITY OF MASSACHUSETTS (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114445-A1 | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections | MPHOSPH6, MRPS18A, PNP | TNF 4650/4885GAA 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.